We typically target companies with the following attributes:

• Innovative companies with differentiated products that address unmet medical needs, improve patient outcomes and reduce overall healthcare expenditures.

• Broad product portfolio with high gross margin potential and existing reimbursement or pathway to reimbursement coverage.

• Compelling clinical and pre-clinical data.

• Companies that offer downside protection through significant collateral value, including intellectual property.

• Companies with liquidity or access to liquidity to fund the business plan to profitability.

• Experienced management team with demonstrated track record of successful product launches and shareholder value creation.

• Public companies with access to capital markets and private companies with strong equity syndicates.

The typical investment size is $20-$150 million+.